MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Moderna, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$226.89+8.88 (+4.07%)

Close on Oct 19, 2026

Market cap: $90.30B
P/E (TTM): –
Dividend yield: –

Moderna, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	1,944	3,236	6,848	19,263	18,471	803	60	135	206	108
Cost of Revenue	868	1,464	4,693	5,416	2,617	8.00	0	0	–	–
Gross Profit	1,076	1,772	2,155	13,847	15,854	795	60	135	–	–
Research & Development	3,132	4,543	4,845	3,295	1,991	1,370	496	454	410	275
General & Administrative	1,018	1,174	1,549	1,132	567	188	110	94	65	57
Advertising Expenses	133	146	204	121	0	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	606	548	475	332
Total Costs & Expenses	5,018	7,181	11,087	9,843	5,175	1,566	606	548	–	–
Operating Income	-3,074	-3,945	-4,239	9,420	13,296	-763	-546	-413	-269	-224
Interest & Investment Income	314	425	421	200	18	25	39	27	15	11
Other Non-Operating Income	-8.00	-87	-124	-45	-29	-6.00	-8.00	1.84	-1.88	-2.71
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	–	–	–	–	-0.24	-0.32	-0.89	0	0
Pretax Income	-2,768	-3,607	-3,942	9,575	13,285	-744	-515	-384	-256	-215
Income Tax Expense	54	-46	772	1,213	1,083	3.00	-1.00	0.33	-0.08	1.04
Net Income	-2,822	-3,561	-4,714	8,362	12,202	-747	-514	-385	-256	-216
Net Income to Common	–	–	–	–	–	-747	-514	-402	-270	-230
EPS (Basic)(per share)	-7.26	-9.28	-12.33	21.26	30.31	-1.96	-1.55	-4.95	-4.18	-3.79
EPS (Diluted)(per share)	-7.26	-9.28	-12.33	20.12	28.29	-1.96	-1.55	-4.95	-4.18	-3.79
Shares Outstanding (Basic, Weighted)(shares)	389	384	382	394	403	381	331	81	64	61
Shares Outstanding (Diluted, Weighted)(shares)	389	384	382	416	431	381	331	81	64	61
EBITDA	-2,863	-3,760	-3,622	9,768	13,528	-732	-515	-388	-249	-209

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 23.4%
Operating margin: -149.0%
Net margin: -141.4%
Return on equity, FY2025: -28.9%

Financial strength

Current ratio: 2.29
Debt to equity: 0.09
Debt to assets: 5.4%
Cash to current liabilities: 68.0%

Valuation

P/E ratio: –
Price to sales: 40.53
Price to book: 13.36
Dividend yield: –